Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes | Zendy

Olusola Olalekan Elekofehinti | Zendy; Oluwamodupe Cecilia Ejelonu | Zendy; Jean Paul Kamdem | Zendy; Oluwaseun Benedicta Akinlosotu | Zendy; Ayodeji Famuti | Zendy; Damilare Desmond Adebowale | Zendy; Opeyemi Iwaloye | Zendy; Yetunde Irinyemi Bulu | Zendy; Ige Joseph Kade | Zendy; João Batista Teixeira da Rocha | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Discovery of potential visfatin activators using in silico docking and ADME predictions as therapy for type 2 diabetes

Author(s) -

Olusola Olalekan Elekofehinti,

Oluwamodupe Cecilia Ejelonu,

Jean Paul Kamdem,

Oluwaseun Benedicta Akinlosotu,

Ayodeji Famuti,

Damilare Desmond Adebowale,

Opeyemi Iwaloye,

Yetunde Irinyemi Bulu,

Ige Joseph Kade,

João Batista Teixeira da Rocha

Publication year - 2018

Publication title -

beni-suef university journal of basic and applied sciences

Language(s) - English

Resource type - Journals

eISSN - 2314-8543

pISSN - 2314-8535

DOI - 10.1016/j.bjbas.2018.02.007

Subject(s) - adme , nicotinamide phosphoribosyltransferase , chemistry , pharmacology , protein data bank (rcsb pdb) , druggability , peroxisome proliferator activated receptor , rosiglitazone , docking (animal) , lipinski's rule of five , in silico , chembl , biochemistry , receptor , medicine , drug discovery , enzyme , in vitro , nad+ kinase , nursing , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research